Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

Here is how ResMed (RMD) and Compass Therapeutics, Inc. (CMPX) have performed compared to their sector so far this year.

Medical device company ResMed (NYSE:RMD) in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit ...

ResMed (RMD) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.69 per share.

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem, designed to ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact ...

SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026. Other financial results: Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea. The NightOwl testing device, about the size of a quarter, is worn on the user ...

ResMed's shares have fallen 37% due to struggles with profitability and investor fears of weight loss drugs, but I believe in its long-term potential. The company reported a 16% increase in revenue ...

ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the average ...

NEW DELHI--(BUSINESS WIRE)--ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general ...